Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Becton, Dickinson and Company    BDX

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Becton Dickinson and : BD Launches New Automated Flow Cytometry Sample Preparation Instrument with CE-IVD Certification

share with twitter share with LinkedIn share with facebook
share via e-mail
03/26/2019 | 06:00am EST

FRANKLIN LAKES, N.J., March 26, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE-IVD certification for the BD FACSDuet™ automated flow cytometry system. The new fully automated sample preparation instrument enables clinical laboratories to improve their efficiency by reducing errors and limiting the manual user interactions required to run assays on the BD FACSLyric™ clinical flow cytometer.

BD FACSDuet™ clinical sample preparation system integrates with the BD FACSLyric™ flow cytometer

The BD FACSDuet™ system builds new capabilities into the BD portfolio of clinical flow cytometry solutions. Collectively, these solutions may help clinical laboratories improve accuracy and repeatability of their assays by minimizing manual steps that can introduce errors.

"The BD FACSDuet system enables us to increase our laboratory's efficiency and throughput, replacing manual processes with automated ones that are traceable and that can be automatically transferred and recorded in our laboratory information system providing a complete audit trail," said David Bloxham, principal biomedical scientist at the Hemato-Oncology Diagnostic Service (HODS) at Cambridge University Hospital NHS Trust.  

Physical integration between the BD FACSDuet™ system and the BD FACSLyric™ clinical flow cytometer allows technicians to load samples and reagents onto the BD FACSDuet™ system and receive data once the samples are fully processed from the BD FACSLyric™ clinical flow cytometer. Data integration using the BD FACSLink™ middleware solution, offers bidirectional communication between the instruments and connectivity with laboratory information systems (LIS).

"The introduction of the BD FACSDuet system is the natural continuation of our 40 year history of making reliable flow cytometry solutions that are more robust and easier to use," said John Ledek, worldwide president of Biosciences for BD. "Automation solutions for flow cytometry can go a long way towards improving accuracy and standardization from instrument to instrument providing the consistent results that clinicians depend on to inform patient care."

The BD FACSDuet™ automated flow cytometry system is available as an in vitro diagnostic (IVD) instrument in Europe and is targeted to be available in other geographies as soon as regulatory milestones are secured. The current platform automates the lyse-no-wash process. Existing systems can be field upgradeable as laboratory needs evolve. For more information, visit bdbiosciences.com/eu

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.

Contacts:

Gwen Gordon

Monique N. Dolecki

BD Public Relations

BD Investor Relations

858.812.3724

201.847.5378

gwen.gordon@bd.com

monique_dolecki@bd.com

 

(PRNewsfoto/BD (Becton, Dickinson and Compa)

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-launches-new-automated-flow-cytometry-sample-preparation-instrument-with-ce-ivd-certification-300818084.html

SOURCE BD (Becton, Dickinson and Company)


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BECTON, DICKINSON AND COMP
02/17BECTON DICKINSON AND : Standardized Incubation and Imaging System Now Available ..
PU
02/13Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Bec..
BU
02/13BECTON DICKINSON AND : BD - Babson Diagnostics Announce Strategic Partnership Ag..
AQ
02/13BECTON DICKINSON AND : BD Collaborates with Fleming Fund to Help Combat Threat o..
PR
02/12BECTON DICKINSON AND : BD, Babson Diagnostics Announce Strategic Partnership Agr..
PR
02/12BECTON, DICKINSON AND COMPANY : Report
CO
02/10BECTON, DICKSON AND COMPANY ALERT : Bragar Eagel & Squire, P.C. is Investigating..
BU
02/07Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against ..
BU
02/07THE LAW OFFICES OF FRANK R. CRUZ : Announces Investigation on Behalf of Becton, ..
BU
02/07BECTON, DICKINSON AND COMPANY : Report
CO
More news